Format

Send to

Choose Destination
Neurogastroenterol Motil. 2017 Mar;29(3). doi: 10.1111/nmo.13038.

Cannabinoids as gastrointestinal anti-inflammatory drugs.

Author information

1
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Abstract

In this mini-review, we focus on the potential of the endocannabinoid system as a target for novel therapies to treat gastrointestinal (GI) inflammation. We discuss the organization of the endocannabinoid signaling and present possible pharmacological sites in the endocannabinoid system. We also refer to recent clinical findings in the field. Finally, we point at the potential use of cannabinoids at low, non-psychoactive doses to counteract non-inflammatory pathological events in the GI tract, like chemotherapy-induced diarrhea, as evidenced by Abalo et al. in the rat model.

KEYWORDS:

endocannabinoid metabolism; gastrointestinal tract; inflammation; “classical” and “non-classical” cannabinoid receptors

PMID:
28239924
DOI:
10.1111/nmo.13038
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center